Ashley Fugate
Payments from drug & device makers
Across 72 payments — averaging $76.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$4K
- Lilly USA, LLC$146
- Novo Nordisk$141
- AbbVie$128
- GSK$99
- Dexcom, Inc.$97
- plus $694 from 24 others
What the payments were for
- Speaking & faculty fees$4,18076%
- Food & beverage$1,32024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 5 | $4,195 |
| Lilly USA, LLC | 4 | $146 |
| Novo Nordisk | 6 | $141 |
| AbbVie | 6 | $128 |
| GSK | 6 | $99 |
| Dexcom, Inc. | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Merck | 3 | $68 |
| Amgen | 4 | $57 |
| Novartis | 3 | $47 |
| Insulet Corporation | 3 | $39 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Corium, LLC | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $31 |
| Bayer | 2 | $30 |
| Lundbeck LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Abbott | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$4,180
How this compares
$5,500 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,408 |
| Atorvastatin Calcium | 70 | $688 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $649 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $461 |
| Metoprolol Succinate | 16 | $389 |
| Lisinopril | 46 | $350 |
| Losartan Potassium | 41 | $342 |
| Omeprazole | 23 | $303 |
| Mirtazapine | 18 | $302 |
| Levothyroxine Sodium | 24 | $194 |
| Amlodipine Besylate | 30 | $192 |
| Glipizide | 15 | $187 |
| Hydroxyzine Hcl | 14 | $172 |
| Famotidine | 16 | $170 |
| Chlorthalidone | 11 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $99 | $16,40822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Niles
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.